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Abstract
Background: To define the dosimetric coverage of level I/II axillary volumes and the lung volume irradiated in
postmastectomy radiotherapy (PMRT) following tissue expander placement.
Methods and Materials: Twenty-three patients were identified who had undergone postmastectomy radiotherapy
with tangent only fields. All patients had pre-radiation tissue expander placement and expansion. Thirteen patients
had bilateral expander reconstruction. The level I/II axillary volumes were contoured using the RTOG contouring
atlas. The patient-specific variables of expander volume, superior-to-inferior location of expander, distance between
expanders, expander angle and axillary volume were analyzed to determine their relationship to the axillary volume
and lung volume dose.
Results: The mean coverage of the level I/II axillary volume by the 95% isodose line (VD95%) was 23.9% (range 0.3 -
65.4%). The mean Ipsilateral Lung VD50% was 8.8% (2.2-20.9). Ipsilateral and contralateral expander volume
correlated to Axillary VD95% in patients with bilateral reconstruction (p = 0.01 and 0.006, respectively) but not those
with ipsilateral only reconstruction (p = 0.60). Ipsilateral Lung VD50% correlated with angle of the expander from
midline (p = 0.05).
Conclusions: In patients undergoing PMRT with tissue expanders, incidental doses delivered by tangents to the
axilla, as defined by the RTOG contouring atlas, do not provide adequate coverage. The posterior-superior region
of level I and II is the region most commonly underdosed. Axillary volume coverage increased with increasing
expander volumes in patients with bilateral reconstruction. Lung dose increased with increasing expander angle
from midline. This information should be considered both when placing expanders and when designing PMRT
tangent only treatment plans by contouring and targeting the axilla volume when axillary treatment is indicated.
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Introduction
Mastectomy is a component of therapy for many
women with breast cancer, both in the locally advanced
and early stages. Recently, several institutions have
reported increased mastectomy rates owing to several
factors including MRI use, genetic testing, shifting
patient preference and improved breast reconstruction
options [1,2].
Post-mastectomy breast reconstruction rates have
increased in the past 3 decades [3]. Options regarding
timing of reconstruction include immediate, delayed,
and most recently immediate-delayed. Currently,
between 25-42% of women undergo immediate recon-
struction and expander placement is a frequently uti-
lized modality [4,5]. Delayed-immediate reconstruction
using tissue expanders is an attractive option in patients
requiring radiation because of the decreased
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not radiating autologous tissue or a permanent implant
[6,7].
Post-mastectomy radiation therapy (PMRT) is indi-
cated in many of these patients to improve local control
and overall survival [8-11]. As curability supersedes
cosmesis in these patients, it is important to ask the
question: “Does immediate reconstruction with tissue
expanders impact the quality of PMRT?” Studies show
that the unique geometry of immediate reconstruction
using various reconstruction modalities can compromise
coverage of the chest wall and internal mammary nodes
and increase lung and heart dose [12-14]. These studies
included few women with expanders and most patients
had regional nodal irradiation.
Although axillary dose has been addressed in the
breast-conservation setting it has not been studied in
reconstructed patients. Expanders contain 20-30%
more saline compared with the final implant. There-
fore, it is important to analyze the population of
women with tissue expanders. Recent attempts to elim-
inate axillary dissection with small numbers of positive
nodes on sentinel node biopsy in early stage breast
cancer are promising and do not appear to compro-
mise outcomes in appropriately selected women who
receive breast only radiation with tangents [15]. In
light of this new paradigm, the dose delivered to the
axilla is increasingly important as incidentally delivered
axillary dose will be relied on to control potential resi-
dual disease. The purpose of this study is to define the
dosimetric coverage of axillary volumes (level I/II) and
the lung volume irradiated in patients treated with tan-
gent fields following mastectomy and tissue expander
placement and to identify variables that impact dose to
these structures.
Methods and Materials
Between 2006- 2010 a cohort of twenty-three patients
who had undergone postmastectomy radiotherapy fol-
lowing tissue expander placement and expansion was
identified. IRB approval was obtained for the study.
Characteristics of the population are in Table 1. The
study cohort had a tissue expander placed on the
radiated side prior to radiation as part of a delayed-
immediate reconstruction paradigm. Patients were
excluded who had a reconstruction modality other than
tissue expander such as an implant or autologous tissue
without an expander. Patients with regional nodal radia-
tion were allowed, however, these patients were
replanned with tangents only. Therefore, no treatment
plans incorporated a supraclavicular, internal mammary
or posterior axillary boost field. None of the patients
received a boost. Inverse-planned IMRT was not
allowed.
Table 1 Patient and Treatment Characteristics
Characteristic
Age (n = 23) 49 (25-71)*
Race
White 16
AA 6
Hispanic 1
Tumor Laterality
L1 6
R4
B/L 3
Tumor Location†
UOQ 9
LOQ 2
UIQ 4
LIQ 2
Chest Wall 1
Overlapping 4
Unknown 1
Histology
IDC 21
ILC 2
Nodal Surgery Radiated Side
SLNB alone 4
ALND 19
Type of Reconstruction
Ipsilateral Alone 10
Bilateral†† 13
Expander Location
Sub Pec Major 33
Sub Latissimus Flap§ 2
Unknown 1
Clinical Stage
Tis|| 3
IA 5
IIA 7
IIB 7
IIIA 2
Unknown 2
Pathologic Stage
ypTis 1
pTis 2
ypT0N0 4
ypIA 3
ypIIA 2
pIIA 3
ypIIB 2
pIIB 5
ypIIIA 3
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Page 2 of 8All patients underwent CT simulation from the mand-
ible through the lungs using 3 mm slices in the supine
position with an indexed breast board. No patient had
their ipsilateral or contralateral expander deflated prior
to or during radiation therapy. Tangents were designed
to incorporate the chest wall with expander. In no
patient were the tangents designed to treat the axilla.
Field borders were initially defined on the CT simula-
tion and were as follows: superior - base of clavicular
head, inferior - 2 cm below the contralateral breast,
medial - mid-sternum, lateral - mid-axillary line or
appropriately lateral to insure adequate coverage of the
most lateral extent of the expander. In case of bilateral
reconstruction, the inferior border was placed in the
area reasonably thought by the treating physician to
include the pre-mastectomy breast extent.
Treatment planning was performed using step-and-
shoot forward-planned IMRT using opposed tangential
beams. A field-in-field technique was used to achieve
dose homogeneity of 98 - 105% within the CTV. Half-
beam blocks were used to prevent beam divergence into
the lung. The prescription was normalized to a point
just superficial to the surface of the pectoralis major in
a plane perpendicular to the central axis at mid-separa-
tion. The prescription was delivered to the isodose line
which best covered the breast CTV. This line was
usually the 98-99% isodose line. The tangent angles
were designed to include a minimum of lung tissue
while maximizing coverage of the CTV.
Axillary levels I and II were contoured retrospectively
using the RTOG contouring atlas [16]. Dose distribu-
tions to volumes of interest were determined using dose
volume histograms. The following variables were exam-
ined to determine their relationship to the axillary
VD95% and lung VD50%: Superior-to-inferior location of
expander, expander angle, intra-expander distance
expander volume and axillary volume. The superior-to-
inferior location of the expander was defined as the dis-
tance between the inferior border of the humeral head
and the superior border of the expander. To normalize
this to patient height, the distance between the humeral
head and the tip of the xiphoid process was also
recorded. The expander angle was defined as the angle
between the patient’s sagittal midline and the most lat-
eral border of the expander in the axial plane (Figure 1).
Intra-expander distance was only recorded in patients
with bilateral reconstruction and was defined as the clo-
sest distance between the most medial portions of the
expanders. Lung VD50% was chosen because the 50% iso-
dose line corresponds to the medial border of the half-
beam blocked treatment fields, thus it should correlate
with variables that change the treatment geometry. Also,
the median prescription dose was 50 Gy; therefore the
50% isodose line corresponds to 25 Gy which is approxi-
mately the same as 20 Gy which has been shown to cor-
relate with pneumonitis rates.
Summary statistics describe the various patient char-
acteristics. Pearson correlation coefficients and their
Figure 1 Measurement of expander angle. Lateral location of the
expander defined by the expander angle (black arrow) measured
on the axial slice with the most lateral expander location from
midline to the lateral expander border in patient with a small (30° -
top) and large (48° - bottom) angle.
Table 1 Patient and Treatment Characteristics (Continued)
pIIIA 1
Systemic Therapy
Neoadjuvant 13
Adjuvant 10
* Median (range)
† Irradiated side only
†† 3 for contralateral synchronous primary and 10 prophylactically
§ 1 on irradiated side, 1 contralateral
|| All Tis had contralateral invasive disease
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ship between the axillary VD95%, lung VD50%, and patient
and expander physical characteristics.
Results
Patient, tumor, and treatment characteristics are shown
in table 1. The median patient age was 49. Nineteen
patients had a full axillary dissection while 4 had senti-
nel node biopsy alone. Thirty-six breasts were recon-
structed in 23 patients - 13 patients with bilateral
procedures and 10 ipsilateral only. The most common
type of reconstruction was a subpectoral expander
occurring in 30 breasts. Two patients had the expander
placed below a pedicled latissimus myocutaneous flap.
All patients received chemotherapy, 57% received it
neoadjuvantly and 43% adjuvantly.
Table 2 shows descriptive statistics of the metrics
that were analyzed. The mean level I/II axillary volume
was 117.6 cm
3 (range 49.7 - 192.9 cm
3) and the mean
volume of the level I/II axilla covered by the 95% line
was 31.6 cm
3 (range 0.4-90.6 cm
3)( F i g u r e2 ) .N o
patient had complete coverage of the level I/II axillary
volume by the 95% isodose line. The mean percent of
the level I/II axillary volume covered by the 95% iso-
dose line was 23.9% (range 0.3-65.4%). Inspection of
the isodose curves revealed that underdosing mainly
occurred in the posterior-superior axilla as shown in
Figure 3. The mean percent of the ipsilateral lung
receiving 50% of the prescription dose was 8.8% (range
2.2-20.9%).
The volume of both the ipsilateral and contralateral
expander and the level I/II axillary volume correlated
with % axillary VD95% (Table 3). The volume of the ipsi-
lateral expander in all patients correlated to axillary
VD95% with an r = 0.51 (p = 0.012). In the thirteen
patients with bilateral reconstruction, the axillary VD95%
correlated with the ipsilateral and contralateral expander
volume (p = 0.01 and 0.006 respectively). However, in
patients with ipsilateral reconstruction only, the axillary
VD95% did not correlate with the expander volume (p =
0.60). The contralateral expander volume correlated to
the ipsilateral expander volume with an r of 0.95. The
superior-to-inferior position of the expander as mea-
sured from the humeral head did not correlate to the
axillary dose. This also held true when this distance was
normalized to the patient’s thoracic size using the hum-
eral head to xiphoid process distance. Neither the dis-
tance between expanders nor the expander angle
impacted axillary VD95%.
Regarding the dose to the lung, only the expander
angle correlated with the lung dose. Neither the super-
ior-to-inferior expander position nor the volume of the
expanders impacted lung dose. Axillary VD95% did not
correlate with the Lung VD50% (r = 0.19).
Discussion
In this study, we found that in patients undergoing post-
mastectomy radiation therapy and delayed-immediate
reconstruction with an inflated expander, the coverage
of the axilla is impacted by the volume of the expander,
but only in patients with bilateral reconstruction. The
underdosing occurred primarily in the posterior-superior
extent of axillary levels I and II. The inferior portion of
the axilla is difficult to define radiographically in this
population of patients. Also, dose to the lung is corre-
lated with the angle of the expander. The superior-to-
inferior extent of the expander did not impact the axil-
lary or lung dose.
A possible explanation for the correlation of axillary
coverage and expander volume in bilaterally recon-
structed patients is that the expander was used as a
Table 2 Descriptive statistics
Range Median Mean StdDev
Axillary Volume* 49.7-192.9 113.6 117.6 41.4
Axillary VD95%† 0.4-90.6 21.9 31.6 28.1
% Axillary VD95% †† 0.3-65.4 24.6 23.9 17
Expander Volume 170-492 437.4 485.4 190.4
Intra-Expander Distance 1.6-13.3 5.8 6.1 2.9
Expander Angle 30-49° 41° 41° 5.2°
Ipsilateral Lung VD50% 2.2-20.9 7.9 8.8 4.2
* All volumes in (cm
3)
† Volume that receives at least 95% of the Rx dose
†† Percent of axilla that receives at least 95% of the Rx dose
Figure 2 Box and whisker plots of the Axillary Volume and
Axillary VD95%
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Page 4 of 8surrogate for the pre-mastectomy breast tissue because
there is no contralateral native breast to use as a tem-
plate. Thus, if larger volume expanders are placed, then
the tangents would be designed to completely
encompass these larger expanders and the amount of
axillary volume incidentally included in the tangents
would increase. Conversely, if smaller volume expanders
were placed, then the tangents would conform to the
Figure 3 Axillary coverage. Coverage by the 95% isodose line as it relates to the axilla in a patient with 65% (left) and a patient with 3% (right)
axillary coverage.
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Page 5 of 8size of the expander and the amount of axillary volume
incidentally included in the tangents would decrease.
A relationship was also seen between the axillary
volume and the axillary VD95%. This may be due to the
difficulty in delineating the inferior extent of axillary
level I in this population of patients. The RTOG con-
touring atlas defines the inferior extent of level I as the
insertion of the pectoralis major into the ribs [16]. We
found this insertion point difficult to locate due to dis-
ruptions in the normal anatomy from the expanders’
subpectoral location and also that an alloderm graft was
often used in the inferior-lateral portion of the expander
to hold it in place on the chest wall.
The only parameter in our study that impacted lung
dose was the lateral location of the expander as measured
by the angle of the expander from midline sagittal plane.
This is likely because deeper tangents are required to
treat the more lateral expanders thus resulting in a higher
lung dose. As modern systemic agents used in breast can-
cer can be associated with a small increased risk of pneu-
monitis, this should be taken into account when placing
expanders. Also, the risk of secondary pulmonary malig-
nancies, especially in smokers, may be reduced by mini-
mizing exposure of the lung [17,18].
Our study findings of poor axillary coverage relative to
the prescription dose agree with data from several inves-
tigators. Aristei et al showed that the median D90 of
levels I and II was 6.75 Gy and 1.75 Gy, respectively, in
breast conserved patients treated with tangents only
undergoing 2D simulation with 3D dose analysis [19].
This represented, as a percent of the prescription dose
of 50 Gy, a median D90 of 13.5% to level I and 3.5% to
level II. Smitt et al showed that in patients with con-
served breasts undergoing CT planning with the goal of
covering the breast alone, a mean axillary dose of more
than 90% of the prescription dose was only achieved in
1o f6p a t i e n t s[ 2 0 ] .A l s o ,u n derdosing occurred in the
posterior-superior portion of levels I and II of the axilla
as in our study. Our data are consistent with McCor-
mick et al who reported that axillary hemostasis clips in
45 patients are included in 2D planned tangents on 38%
of patients and that incomplete clip coverage occurred
in the posterior-superior portion [21]. Krasin et al
reconstructed 2D plans to obtain 3D dose-volume data
in patients treated with standard breast tangents and
found that out of 25 patients, one had more than 95%
coverage of level I and none had more than 95% cover-
a g eo fl e v e lI I .A l s o ,t h em e a nV 20 was 7.5% which is
slightly less than our 8.8% mean amount of lung receiv-
ing 50% of the prescription dose of 50 Gy [22].
Published data also conflicts with our results. Good-
m a ne ta lr e p o r t e dt h a ti np a t i e n t su n d e r g o i n gt a n g e n -
tial only radiation, levels I and II were covered in 8 of 9
patients [23]. Details regarding anatomic boundaries of
the axillary were not provided. However, the anatomic
landmarks for contouring the axilla likely differed from
our study as the RTOG contouring atlas had not been
published. Also, the surgical therapeutic and reconstruc-
tive management of these patients varied.
In a similar investigation to ours, Reed et al performed
an analysis of axillary levels I and II dose using 3D plan-
ning in patients with breast conservation and found that
a mean of 55% of the axilla was covered by the 95% line
which is more than double our finding of 23.9% [24].
Reasons for this difference are that axillary contouring
landmarks were different which could lead to more gen-
erous contouring in well covered areas like low level I
and less generous in poorly covered areas such as in the
posterior-superior direction, an area often underdosed
in our study. Indeed the mean axillary volume in their
study was 146.3 cm
3 compared with 117.6 cm
3 in ours.
However, similar to our study the posterior-superior
area was not well covered. Second, these patients were
not planned with step-and-shoot techniques as in our
study and it is possible that more traditional breast only
irradiation techniques deliver a higher dose to the axilla.
Table 3 Pearson correlation (r) and p values of variables with axillary and lung dose
r value: % Axillary VD95% p value r value: % Ipsilateral Lung VD50% P value
HH to Expander 0.13 0.56 0.005 0.98
HH to Exp/HH to XP 0.16 0.46 0.03 0.88
Expander Angle -0.25 0.24 0.41 0.05
Expander Distance 0.34 0.28 0.50 0.10
Ipsi Exp Volume 0.51 0.012 0.01 0.95
Ipsi Exp Vol* 0.18 0.60 0.21 0.54
Ipsi Exp Vol† 0.70 0.01 0.10 0.77
Contralat Exp Volume 0.76 0.006 0.19 0.56
Axillary Volume 0.52 0.011 N/A N/A
* Only patients with ipsilateral expanders
† Only patients with bilateral expanders
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Page 6 of 8A limitation of our study is the small number of
p a t i e n t s .N o n e t h e l e s s ,t oo u rk n o w l e d g ei tr e p r e s e n t s
the largest study of axillary and lung doses in delayed-
immediate reconstructed women undergoing modern
radiotherapy, many of whom had bilateral
reconstruction.
Our results are important for several reasons. Recent
studies have shown that both mastectomy rates and
reconstruction rates are increasing [1-3]. As such we
must analyze this group of post-mastectomy women
with respect to delivery of radiation and outcomes. In
addition, the results of our study have implications in
light of the recently reported ACOSOG Z0011 trial
which showed that women with less than 3 positive
nodes on sentinel node biopsy who received tangent
only radiation had overall survival, locoregional control
and disease-free survival that is not inferior to those
who received axillary node dissection and the same
radiation [15]. Although in this trial women received
breast conservation and not mastectomy, as in our
study, the results may be applicable to women who
choose mastectomy but were otherwise eligible for the
trial. As these women may decide to pursue post-mas-
tectomy reconstruction, it is important to quantify the
dose to the axilla. This is particularly important consid-
ering 27.3% of women on the ACOSOG trial with posi-
tive sentinel nodes had additional metastatic nodes on
subsequent axillary dissection.
Conclusions
Efforts to reduce morbidity by decreasing the extent of
axillary dissection must be accompanied by comprehen-
sively quantifying dose and factors that impact dose to
the axilla in all subgroups of patients, including those
with tissue expanders. This information will be helpful
both for recurrence and morbidity endpoints. Our study
is the first report of axillary dose in women with tissue
expanders undergoing breast only irradiation. This ana-
l y s i ss u g g e s t st h a ti np a t i e n t su n d e r g o i n gP M R Tw i t h
tissue expanders in place, incidental doses delivered by
opposed tangents to the Level I and II regions, as
defined by the RTOG contouring atlas, do not provide
adequate dosimetric coverage of these regions. This
should be considered when designing PMRT treatment
fields. However, the clinical significance of underdosing
this volume is unknown. In addition, the increased lung
dose associated with the lateral expander location
should be taken into consideration when placing expan-
ders. How axillary and lung coverage affects endpoints
such as axillary recurrence, pulmonary toxicity, locore-
gional failure, distant metastasis and morbidity remains
to be seen and should be the subject of future
investigations.
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